Versant Capital Management’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$436K Buy
12,235
+523
+4% +$16.5K 0.04% 357
2026
Q2
$322K Sell
11,712
-1,908
-14% -$50.7K 0.03% 439
2026
Q1
$365K Buy
13,620
+2,965
+28% +$88.9K 0.04% 361
2025
Q4
$328K Sell
10,655
-213
-2% -$6.64K 0.04% 331
2025
Q3
$333K Buy
10,868
+301
+3% +$7.34K 0.05% 328
2025
Q2
$218K Buy
10,567
+1,843
+21% +$37.8K 0.03% 413
2025
Q1
$171K Buy
8,724
+8,002
+1,108% +$168K 0.03% 468
2024
Q4
$15.1K Buy
+722
New +$15.9K ﹤0.01% 1179
2023
Q4
– Sell
-88
Closed -$3.1K – 1957
2023
Q3
$3.1K Hold
88
– – ﹤0.01% 1152
2023
Q2
$3.34K Hold
88
– – ﹤0.01% 1178
2023
Q1
$3.32K Buy
+88
New +$3.38K ﹤0.01% 1096

Other funds holding GMAB

Versant Capital Management's GMAB Position: Q3 2026 in Review

Versant Capital Management increased its Genmab (GMAB) stake by 4.5% in Q3 2026, buying an estimated $16.5K and bringing the position to 12,235 shares worth $436K. The position accounts for 0.04% of the portfolio, ranked #357.

Versant Capital Management first reported a position in GMAB in Q1 2023 and has held it in 11 quarters since. 331 funds tracked by Wall St. Rank hold GMAB as of Q3 2026.

  • Versant Capital Management held 12,235 shares of Genmab worth $436K as of Q3 2026.
  • Versant Capital Management bought 523 Genmab shares in Q3 2026, an estimated $16.5K.
  • Genmab made up 0.04% of Versant Capital Management's portfolio in Q3 2026, its #357 holding.
  • Versant Capital Management first reported a position in Genmab in Q1 2023 and has held it in 11 quarters since.
  • 331 funds tracked by Wall St. Rank held Genmab as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.